ClinicalKey AI vs OpenEvidence
The publisher's answer against the newcomer's, and they are grounded in different things. ClinicalKey AI reads Elsevier's own curated library, enumerates it source by source, refreshes it daily and links each generated statement to the specific paragraph it came from, which is the best provenance mechanism in this category. OpenEvidence reads the current literature through partnerships with the New England Journal of Medicine, JAMA and Cochrane, and carries something no publisher owned product here has: eleven independent studies evaluating it, found through a systematic review it did not commission. The trade is the business model. Elsevier is paid by subscription and publishes no price. OpenEvidence is free because pharmaceutical and device advertising sits beside the answers, governed by a published policy that is worth reading before you decide the trade is acceptable.
- Provenance runs to the paragraph. A generated answer links to the specific passage in the source it came from rather than to the document, which is the finest granularity available in this category.
- The corpus is enumerated rather than described, with named reference texts, society guidelines from bodies spanning cardiology, endocrinology and emergency medicine, named journals and government publications, refreshed daily.
- A published clinician centred evaluation framework applied to its own generative output, plus five responsible AI principles, available in more than 50 countries with multi language support.
- Eleven independent studies published between 2024 and 2026 evaluating this product, identified through a systematic review following PRISMA, which is external scrutiny no publisher owned product here has attracted.
- It reaches the current literature rather than a back catalogue, through official partnerships with the New England Journal of Medicine, JAMA and its eleven specialty journals, and Cochrane Systematic Reviews.
- Free to verified United States clinicians with web and native mobile applications, plus enterprise Epic embedding documented at Mount Sinai across seven hospitals, against a product whose only published price is a free year for students.
Side by Side
| Axis | C ClinicalKey AI |
O OpenEvidence |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
OpenEvidence is funded by pharmaceutical and medical device advertising shown alongside clinical answers, and its published advertising policy is the artifact to read before deciding whether that is acceptable in your setting. ClinicalKey AI publishes no rate card and no security attestation or trust centre, and its HIPAA claim carries a qualifier rather than an inspectable agreement.
Neither product publishes a bias evaluation, subgroup performance analysis or error taxonomy for the generative layer, which is the shared gap in this category: both address the fabricated citation well and neither addresses an interpretive error sitting underneath an accurate one.